Industry Experts

Dr. Stefanie Mandl-Cashman is a USCF- and Stanford-trained immunologist with over 20 years of leadership in the biotechnology sector, currently serving as Chief Scientific Officer at Indapta Therapeutics. With deep expertise in immunotherapies—including adoptive cell therapies, bi-specific antibodies, and vaccine-based approaches—SMC drives the scientific, strategic, and operational direction of high-impact pipeline programs from concept through clinical development.

Throughout a distinguished career, Dr. Mandl-Cashman has built and led high-performance research organizations focused on translating cutting-edge academic discoveries into commercially viable therapies. A recent milestone includes the identification of a therapeutic opportunity in multiple sclerosis, culminating in a successful IND filing and FDA clearance in August 2024—marking Indapta’s entry into the autoimmune space.

Previously, Dr. Mandl-Cashman pioneered the scientific and technical development of PACT Pharma’s first-in-human personalized adoptive TCR-T cell therapy, spearheading the creation of proprietary platforms such as a novel TCR Isolation Technology, non-viral precision genome engineering platform and cell manufacturing processes.

Dr. Mandl-Cashman holds a PhD in Immunology and is recognized as a forward-focused executive committed to transforming innovative science into clinical realities.